Short Interest in Enfusion, Inc. (NYSE:ENFN) Declines By 14.1%

Enfusion, Inc. (NYSE:ENFN) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 1,520,000 shares, a decrease of 14.1% from the September 30th total of 1,770,000 shares. Based on an average daily volume of 376,900 shares, the short-interest ratio is presently 4.0 days. Currently, 3.1% of the shares of the company are sold short.

Enfusion Stock Performance

NYSE ENFN traded down $0.10 during mid-day trading on Thursday, reaching $8.91. 256,637 shares of the stock were exchanged, compared to its average volume of 364,632. The company has a market capitalization of $1.14 billion, a P/E ratio of 222.75, a P/E/G ratio of 2.46 and a beta of 0.92. The business’s 50 day moving average is $8.72 and its 200-day moving average is $8.85. Enfusion has a 1 year low of $7.52 and a 1 year high of $10.45.

Enfusion (NYSE:ENFN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Enfusion had a return on equity of 6.17% and a net margin of 1.98%. The firm had revenue of $49.46 million during the quarter, compared to analyst estimates of $50.27 million. Equities analysts predict that Enfusion will post 0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enfusion

A number of hedge funds have recently bought and sold shares of ENFN. Vanguard Group Inc. grew its holdings in Enfusion by 1.4% in the first quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company’s stock valued at $33,792,000 after purchasing an additional 51,670 shares during the period. Wasatch Advisors LP lifted its position in shares of Enfusion by 34.2% during the 1st quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock valued at $7,327,000 after buying an additional 201,771 shares in the last quarter. Impax Asset Management Group plc grew its stake in Enfusion by 25.4% in the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after acquiring an additional 136,948 shares during the period. Scalar Gauge Management LLC increased its holdings in Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after acquiring an additional 110,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Enfusion by 57.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after acquiring an additional 191,436 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.